The department has an extensive local network of referring departments. In addition, we have a formalized collaboration with the Department of Haematology at Aalborg University Hospital regarding the diagnosis, therapy and follow-up of all malignant haematological disorders. Patients are diagnosed in a multidisciplinary approach encompassing not only morphology and immunohistochemistry. They also undergo a advanced analyses with flow cytometry, cytogenetics and molecular biology, performed in the Hemodiagnostic Laboratorywhich is integrated in the department.

In 2009, the department became the 2nd after the Royal State Hospital to perform allogeneic transplantations where donor hematopoietic cells from either a sibling donor or from a donor discovered in an international registry are transplanted into a patient in a non-myeloablative setting. This programme is performed in close collaboration with researchers in Europe and The United States and adjunct professor Finn O. Petersen, Intermountain Blood and Bone Marrow Transplantation Program, Salt Lake City presently acts as consultant for the development of an accreditation program conforming to the international JACIE system. JACIE accreditation is expected by the end of 2016.

In the area of acute myeloid leukaemia (AML), the department is actively participating in the British AML Studies. This participation ensures that patients receive internationally recognized cytoreduction and are part in efforts refining these. Within the area of T-cell derived lymphomas, professor Francesco d’Amore is heading a team of international researchers treating these patients with targeted therapies including monoclonal antibodies such as Alemtuzumab directed against the CD52 antigen.